Latest Content

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.

Guillermo Garcia-Manero, MD, discusses the phase 3 GLORA-4 study of lisaftoclax plus azacitidine in higher-risk MDS.

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.

A global analysis led by Dana-Farber combined patient data from 6 major clinical trials to compare 2 immunotherapies for advanced non–small cell lung cancer.

A SEER analysis showed that immune checkpoint inhibitors better improved OS for younger patients vs older patients with advanced renal cell carcinoma.

Raji Shameem, MD, discusses the continuing evolution of the frontline treatment landscape of metastatic pancreatic cancer.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.

WJ01024 alone and in combination with ruxolitinib was safe and generated efficacy signals in relapsed/refractory myelofibrosis.

Jonathan Lee, MD, MSc, offers his tips for interviewing for a hematology/oncology fellowship.

Gotistobart received orphan drug designation from the FDA for patients with squamous NSCLC.

Nogapendekin alfa inbakicept plus PD-L1 t-haNK and bevacizumab produced encouraging overall survival data in recurrent glioblastoma.